8

•

FORM PTO-1449

(Use several sheets if necessary)

LIST OF DISCLOSURES CITED BY APPLICANT

U.S. Dept. of Commerce

Patent and Trademark Office

Atty Docket No.

Serial No. 19 234,132

Applicant

Hsei et al. Filing Date

11 Jan 1999

Group

JUN 0 8 1999 S

U.S. PATENT DOCUMENTS

Examiner nitials	-	Document Number	Date	V.S. RATENT DOCUMENTS Name	Class	Subclass	Filing Date
312	1	4,302,531	11.81.77	Foyer		+	
	2	4,179,337	18 12.79	Davis et al.			
11	3	4,732,863	22 33 88	Tomasi et al.			
	4	5,147,537	15 39 92	Sada et al.			
	5,	5,166,322	24 11 92	Shaw et al.			
	ti	5,169,627	08 12 93	Cunningham-Rundles			
	?	5,527,528	18 06 36	Allen et al.			
	8	5,532,150	02 07 95	Snow et al.			
	9	5,595,732	21 01 97	Hakini et al.		1	
-	10	E,620,689	15 04 97	Allen et al.			
	11	E,643,575	01 07 97	Martinez et al.			
1	12	5,661,020	26 08.97	Snow et al.			
1	13	5,670,132	23.09.97	Griffiths et al.			
	14	5,677,426	14 10.97	Fong et al.			
	1.5	5,686,070	11 11.97	Déerschuk et al.		-	
	16	E,695,760	09 12 97	Faanes et al.			
	17	5,698,196	16 12.97	Matsushima et al.			
	18	5,702,946	30 12.97	Doerschuk et al.			
21/2	19	5,707,622	13,01,93	Fong et al.			

FOREIGN PATENT DOCUMENTS

770,628 WD 92 04372 WD 94 12219 WD 94 21235	02.05.07 19.03.92 09.06.94	PCT PCT				
wo 94-12219		FIGT				
	39.36.44	1	1 \			
Wh 94+21235		PCT				
1	29.09.94	PICT				
::5 95°11987	04.05.95	PCT	`.	ľ		
WO 95 15769	15.06.45	POT	\ \rac{1}{2}			
WO 95 23813	38.19.95	POT		√ :		
00 95 23965	08.09.95	PGT				
NO 95 32223	31.11.95	PCT		1		
HO 96 12576	01.32.96	POT Abstract Cody		,		
WG 96 09305	24.01.96	PCT				
MO 96 34015	31.11.96	POT				
WD 96 44731	19.11.96	PCT	*			
WO 97 13847	27.; .; "	POT	\frac{1}{2}			
	WO 95 15769 WO 95 13813 WO 95 23865 WO 95 32103 WO 96 32576 WO 96 34015 WO 96 41731	WO 95 15769 15.06.05 WO 95 13813 08.19.95 WO 95 23865 08.29.95 WO 95 30203 30.11.95 WO 96 10576 01.01.06 WO 96 19305 24.11.96 WO 96 40731 19.11.96	WO 95 15769 15.06.45 PCT WO 95 13813 08.09.95 PCT WO 95 23865 08.09.95 PCT WO 95 32103 30.11.95 PCT WO 96 12576 01.01.96 PCT WO 96 34015 24.01.96 PCT WO 96 41731 19.11.96 PCT	WO 95 15769 15.06.45 PCT WO 95 13813 08.19.95 PCT WO 95 23865 08.09.95 PCT WO 95 32103 30.11.95 PCT WO 96 12576 01.01.96 PCT WO 96 34015 24.01.96 PCT WO 96 41731 19.11.96 PCT	WO 95 15769 15.36.95 PCT WO 95 23813 38.19.95 PCT WO 95 23865 03.29.95 PCT WO 95 30203 30.11.95 PCT WO 96 10576 01.01.96 PCT WO 96 34015 31.11.96 PCT WO 96 40731 19.11.96 PCT	WO 95 15769 15.06.95 PCT WO 95 13813 08.19.95 PCT WO 95 23865 08.09.95 PCT WO 95 32103 00.11.95 PCT WO 96 72576 01.01.96 PCT WO 96 34115 00.11.96 PCT WO 96 41731 19.11.96 PCT

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM	PTO-	1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. p109584-1A Applicant		Serial No. 19 234 / 180			
		SCLOSURES CITED B reral sheets if necessary	()	O 1 P & C65	Hs Fil	1p 3-16-4'4	1644				
Examiner Initials		Document Number	Date	FOREIGN PATENT DOCUME	NIS	Class	Subclass	Transla Yes	ation No		
7.12	34	WO 98 25971	18.06.98	PCT							
JVZ	35	WO 98 37200	27.08 98	OSURES (Including Author, Title, Da	ite. Perti	inent Pages, et	c.)		<u> </u>		
20.0	36	New York: Wiley, C	vis, "Soluble Chapter 13, pps	Polymer- Endyme Adducts" <u>Endyr</u> . 367-383 (1481)	mes as	Drugs, Holce	enberg,JS;		J eds.,		
	37			<u>eference</u> (Product information ny pps. 917=418 (1994)), 48 +	dition, Mönt	vale, NJ:M	ledical			
	38			or attachmen, of antibodies to r cells" <u>Biochimica et Biophy</u>							
	39	Anderson and Tomasi, "Polymer modification of antibody to eliminate immune complex and Fc binding" Journal of Immunological Methods 109(1):37-42 (Apr 22, 1983)									
	40	Beauchamp et al., "A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and α_2 -macroglobulin" Analytical Biochemistry 1×1(1):25-33 (1933) Brooks and Stocks. "Use of polyacrylamide-derivatized antibody in dextran-poly(ethylene glycol) systems"									
	41	Methods in Enzymo	<u>logy</u> 223:390-3	95 (1994)							
	42			n with monomethoxypolyethylene Journal of Immunology 154(7)				ral epit	opes		
	45	Practical Approact pps. 291:338 (199	<u>h</u> , Hoogenboom, (6)	uses of Fab: fragments from : H., McCafferty, J., Chiswell	, D. ed	ds., Oxford,	UK:IRL Pre	ess, Chap	ter 13,		
	44	reductive alkylat	ion" <u>Biogonjug</u>	CD4 immunoadhesin with monomate Chemistry 5(2):133-140 (Ma	ar-Apr	1994)					
	45			logical activities of polyeth tion" <u>Journal of Immunologica</u>		-					
	46	Materials and Pha Press pps. 441-45	rmaceuticals f 2 (1980)	genic Polyethylene Gylcol-Bour or Biomedical Use, Goldberg,E	and Na	akajima,A eds	s., New Yor	k.Academ			
	47	Chromatography B	592(3):263-272								
	48	Delgado et al., "Distinct Influence of PEGylation on the Tumour Localisation of Transferrin and a Tumour-Specific Fab Fragment (F9)" <u>Journal of Cellular Biochemistry</u> (Abstr. A4-101, Keystone Symposium teld at Hilton Head Island, SC, Jan 7-13 1995) Suppl. 19A:171 (1995) The Lando et al., "Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab' fragment by									
	49	poly(ethylene gly	rcol) (PEG) mod	ification" <u>British Journal of</u>	Cancer	2 73(3):175-3	132 (Jan 19	1961			
	5.	Carrier Systems 9	(3-4):249-324								
	5:			nce of human platelet factur							
Th ^E	5.5		e serum albumi	y partitioning synthesis and n and monoclemal antibodies")							
Examine		,				Considered					
	er: / In			Liot citation is in conformance with MP py of this form with next communicati	EP 609:	draw line throu			-		
				,,			110	COMMEDIC	90.200		

FORM PTO-1449	U.S. Dept. of Commerce	Atty Docket No.	Serial No.					
LICT OF DICCU OCUPES SITED BY ADDIUG	O 1 P Ratent and Trademark Office	Applicant	27 234,2 2					
LIST OF DISCLOSURES CITED BY APPLIC	AN	Hsel et al.						
(Use several sheets if necessary)	JUN 0 8 1999 65	Filing Date	Group					
	R DISCLOSURES (Inchiding Author, Title, Date,							
53 polyethylene glycol <u>Bri</u>	tered (Malen Sution of an antibody-e- tish Journal of Cancer 73(11):1323-1327	(Jun 1996)						
54 IL8 to Human Neutrophils' Combining Sites (Poster)	zation of Murine 6G425:An Anti-ILS Mono " <u>1996 Keystone Symposia on Exploring a</u> pps. 1-21 (February 1996)	nd Exploiting Anti	body and Ig Superfamily					
	enicity and pharmacokinetic attributes (ica et Biophysica Acta 1327(2):181-192		lycol)-grafted					
Harris et al., "Synthesis 56 Holym. Chem, Ed. 22(I):34	s and Characterization of Poly(ethylene 41-352 (1984)	Glycol) Derivativ	es" <u>J. Polym. Sci.</u>					
	Haselgrubler et al., "Synthesis and applications of a new poly(ethylene glycol) derivative for the crosslinking of amines with thiols" <u>Bioconjugate Chemistry</u> #(3):242-248 (May-Jun 1995)							
	lal and Leukocyte Forms of IL-3: Conver. 145(9):3033-3040 (Nov 1, 1990)	sion by Thrombin a	nd Interactions with					
Hebert et al., "Interleuk 59	kin-8: A Review" <u>(anger Investigation</u> 1	1(6):743-750 (1993)					
60 228:377-390 (1994)	y(ethylene glycol)-modified antibody in							
	on of Proteins with Polyethylene Glycol meir therapeutic potential." <u>Advanced D</u>							
62 Archives of Allergy & App	responses to polyethylene glycol modif plied Immunology 76(4):324-330 (1985)							
	ally stabilized anti-HER2 immunoliposom iochemistry 36(1):66-75 (Jan 7. 1997)	es: design and tar	geting to human breast					
	al engineering of the moncolonal antibo erapy" <u>Cancer Research</u> 51(16):4310-4315		ene glycol for					
	nylene glycol modification of the monoc 1 & Biophysical Research Communications	•						
	nip of Effective Molecular Size to Syst Modified with Water Soluble Polymers" (15 - 1988)							
Fo et al., "A sensitive e 67 [49:227-235 (1992)	enzyme-linked imminosorbent assay for h	uman interloukin-8	" J. Immunol. Methods					
68 <u>Protein Science</u> (Abstract on July 25-29, 1998) 7(St	ing antibody fragments with PEGylation of 189-M, presented at the Protein Socie (1991, 1):73 (Jul 1998)	ty's Twelfth Sympo	sium in San Diego, CA					
69 conjugates with monomeths	n of antibody responses in rats to muri exypolyethylene glycol" <u>Immunology Lett</u>	ers 30(3):217-252	(May 1992)					
allergenicity of protein Allergy & Applied Immunol	<pre>ion of reaginic antibodies with modified allergens by conjugation to polyethyle logy 56(2):159-170 (1975) function of immunoscenicity of A Mirine A</pre>	me glycol" <u>Interna</u>	tional <u>Archives</u> of.					
g: Chemistry" The 9th Intern	national Congress, of Immunology (abstra-	<u>ct besk)</u> (abstract	#5247) pps. 685 (1995)					
	ic conjugates of xenogeneic monoclonal : long-lasting tolerance to xenogeneic mo 3:10-22 (1988)							
Examiner		ate Considered						
	ther or not citation is in conformance with MPEP include copy of this form with next communication		citation					

-											
FORM	1 PTO-	1449 U.S. Dept. of Commerce	Atty Docket No.	Serial No.							
•		Patent and Trademark Office	P1U85P4-1A	.9 134,143							
LIST	OF DI	COLOCUPED DIVADBLICANT	Applicant Hsei et al.								
1	lea ea	veral sheets if necessary)	Filing Date	Group .							
(()se sev	relatisfieets if fiecessary)	1. Jan 1999	1645/644							
		OTHER DISCLOSURES (Midding Author, Title, Date,	Pertinent Pages, etc.)								
-1" L	73	(Aug 11, 1997)									
	7.4	Maruyama et al., "Targeting efficiency of PEG-immunoliposome-co Advanced Drug Delivery Reviews 24:235-242 (1997)	njugated antibodies	at PEG terminals"							
:	7.5	Mulligan et al., "Inhibition of Lung Inflammatory Reactions in Rats by an Anti-Human IL-8 Antibody" <u>J.</u> <u>Immunol.</u> 150(12):5535-5595 (June 15, 1993)									
	76	Nordwall et al., "IgG and IgE antibody patterns after immunothe modified honey bee venom" <u>Allergy: European Journal of Allergy</u> 1986)	& Clinical Immunolo	<u>gy</u> 41(2):8)-94 (Feb							
	77	Pedley et al., "The potential for enhanced tumour localisation anti-CEA antibody" <u>British Journal of Cancer</u> 70(6):1126-1130 (D		ycol) modification of							
•	78	Sekido et al , "Prevention of lung reperfusion injury in rabbit interleukin-3" <u>Nature</u> 365:654-657 (October 14, 1993)	s by a monoclonal a	ntibody against							
	79	Shahinian and Silvius, "A novel strategy affords high-yield coupling of antibody Fab' fragments to g liposomes" <u>B.ochimica et Biophysica Acta</u> 1239(2):157-167 (Nov 1, 1995)									
	80	Sharp et al "Synthesis and application of a poly(ethylene gly separations in aqueous polymer two-phase systems" <u>Analytical Bi</u>									
	81	(Shearwater Polymers, Inc.'s January 1996 Catalog of Polyethylene Glycol Derivatives) pps. 1-5)									
	82	St. Cohn et al., "Immunologic Therapy for ARDS, Septic Shock, a 103:932-943 (1993)	nd Miltiple-Organ F	ailure" <u>Chest</u>							
	8.3	Stickerling et al., "Immunohistochemical studies on NAP-1/IL-8 Arch. Dermatol. Res. 234:51-85 (1992)	in contact eczema a	nd atopic dermatitis"							
· - , ·	84	Sticherling et al., "Production and Characterization of Monoglo Neutrophil Activating Peptide NAP/IL-3" <u>J. Immunol.</u> 143(5) 1623									
	85	Suzuki et al , "Physicochemical and biological properties of polimmunoglobulin G. Part II. Effect of molecular weight of poly(e. Science, Polymer Edition 1(2):71-94 (1959)	ly(ethylene glycol) thylene glycol) <u>Jo</u>	-coupled urnal of Biomaterials							
	8.6	Suzuki et al , "Preparation and characteristics of magnetite-la poly(ethylene glycol) derivatives" <u>Biotechnology & Applied Bloc</u>	hemistry 21(Pt 3):3	35-345 (Jun 1995)							
	8 7	Tanaka et al , "Synthesis and biological characterization of mo factor" <u>FEBS letters</u> 236(1):467-470 (Aug 1988)	nocyte-derived neut	rophil chémotactic							
	58	Van Damme et al., "Purification of granulocyte chemotactic pept sequence heterogeneity similar to that of β -thromboglobulin" Eq. 181:137-344 (1989)	ropean Journal of B	iochemistry							
	<u>8</u> .9	Veronese et al., "Improvement of pharmacokinetic, immunological by conjugation to linear and branched monomethoxy poly(ethylene 40:199-209 (1996)	glycol)" <u>Journal o</u>	<u>f Controlled Release</u>							
	4.1	Wie et al., 'Suppression of reaginic antibodies with modified a conjugates of common allergens with monomethoxypolyethylene gly the mixed annydride method" <u>International Archives of Allergy &</u>	cols of different m <u>Applied Immunology</u>	olecular weights by [64(1):84-99 (1981)							
	91	Yoshimoto et al., "Chemical modification of tryptophanase from reduce its immunoreactivity towards anti-tryptophanase antibodi	E. coli with polyer	hylene glycol to							
- _A ⁴	92	Yoshimura et al., Neutrophil attractant activation protein-l a rabbit, cDNA cloning and their expression in spleen cells <u>C. I</u>									

*Examiner. Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner

Date Considered

FORM	PTO-	1449	U.S. Dept. of Commerce	Atty Docket No.	Serial No.
	•	•	Patent and Trademark Office	Applicant	37 27 7 7 7
LIST	OF DI	SCLOSURES CITED BY APPLICANT	(DUN 0 8 1999 0 MUL	Hsei et al.	
(L	lse sev	reral sheets if necessary)	JUN 0 0 1335	Filing Date	Group ,
, ,			The state of the s	20 Jan 1999	1545/644
			CLOSURES Liberuding Author, Title, Da		
342	93	Humanized Fab'" (poster prese Meeting in San Francisco, CA	Coupling of Monomethoxypoly(ethented at the American Society for on May 21-25, 1995) pps. 1-27	Biochemistry and Mole	cular Biology FASEB
71/1	94	Zapata et al., "Site-Specific Humanized Fab'" FASEB Journal	Coupling of Monomethoxypoly(eth (Abstract #1238, presented at t .ng in San Francisco, CA on May 2	the American Society fo	or Biochemistry and
				-	
:					
				-	
	07 11				
Examine	er			Date Considered	
		. 4		>// > ¹ /2 -> *	
			r not citation is in conformance with MPE		tation

FORM PTO-1449

(Use several sheets if necessary)

LIST OF DISCLOSURES CITED BY APP

U.S. Dept. of Commerce Patent and Trademark Office

Sheet ____ of Serial No Atty Docket No. 19 234,182 P1185R4-1A

Applicant

Hsei et al.

Filing Date 31 Jan 1999 Group

FOREIGN PATENT DOCUMENTS

Doo	cument Number	Date	Country	Class	Subclass	Translation Yes No
95 WO	99:37779	29.07.99	PCT			
		OTHER DISC	LOSURES (Including Author, Title, Date	e, Pertinent Pages, et	c.)	
96 17	apman et al., " (8):783-783 (Au	Therapeutic a g 1999)	ntibody fragments with prolonged	i in vivo half-liv	/es <u>Nature</u>	<u>Biotechnology</u>
				tion with polyeth	nylene glydd	l" <u>Journal of</u>
					,	
					· · · ·	
			<u></u>			<u> </u>
A D						
i i i i						
						<u></u> .
r	R()		. , , , , , , , ,	Date Considered		5/15/CZ 3117/03
	95 MO Cha 96 17 97 Bic	Chapman et al., 17(3):730-783 (Au Clark et al., "Lo Biological Chemis	OTHER DISC Chapman et al., "Therapeutic a 17(8):780-783 (Aug 1999) Clark et al., "Long-acting gro Biological Chemistry 271(36):2	OTHER DISCLOSURES (Including Author, Title, Date Chapman et al., "Therapeutic antibody fragments with prolonged 17(3):763-783 (Aug 1999) Clark et al., "Long-acting growth hormones produced by conjuga Biological Chemistry 271(36):21969-21977 (Sep. 6, 1996)	OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, et Chapman et al., "Therapeutic antibody fragments with prolonged in vivo half-in 17(3):733-733 (Aug 1999) Clark et al., "Long-acting growth hormones produced by conjugation with polyets Biological Chemistry 271(361:21969-21977 (Sep. 6, 1996) Date Considered	OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) Chapman et al., "Therapeutic antibody fragments with prolonged in vivo half-lives" Nature. 17(9):761-783 (Aug 1999) Clark et al., 'Long-acting growth hormones produced by conjugation with pelyethylene glyco Biological Chemistry 271(36):21969-21977 (Sep. 6, 1996) Date Considered